```html

Warfarin‑Induced Skin Necrosis

Overview

Warfarin‑induced skin necrosis (WISN) is a rare, but potentially life‑threatening, adverse reaction to the anticoagulant warfarin. It typically presents as painful, erythematous plaques that rapidly progress to full‑thickness skin loss (necrosis). The condition most often emerges in the first 3–10 days after initiating warfarin therapy, although cases have been reported after re‑exposure or dose escalation.

Who it affects: Women are affected slightly more often than men (≈55 % vs. 45 %). The majority of cases occur in patients with underlying protein C or protein S deficiency, but it can also occur in patients with normal levels of these natural anticoagulants.

Prevalence: The incidence is estimated at 0.01–0.1 % of all patients starting warfarin (1 in 10,000–100,000). Because it is under‑reported, the true incidence may be slightly higher.<sup>1</sup>

Symptoms

Symptoms typically develop within the first week of therapy and progress quickly. The classic presentation includes:

• Painful, rapidly expanding erythema – often described as a burning or throbbing sensation.
• Edema and induration – the skin feels firm and swollen.
• Purpura or petechiae – small red or purple spots that may coalesce.
• Hemorrhagic bullae – fluid‑filled blisters that may burst, leaving a raw surface.
• Necrotic skin – black or brown eschar indicating tissue death.
• Location – most common on the breasts, thighs, buttocks, trunk, and face; lesions are usually bilateral but can be unilateral.
• Systemic signs – fever, chills, or malaise may accompany severe necrosis.

Atypical presentations can include isolated peripheral necrosis (e.g., fingers or toes) or delayed onset (after >10 days) in patients with protein C deficiency who have been on long‑term warfarin.

Causes and Risk Factors

Pathophysiology

Warfarin blocks the vitamin K–dependent synthesis of clotting factors II, VII, IX, X **and** the natural anticoagulants protein C and protein S. Protein C has a shorter half‑life (≈8 h) than the clotting factors. During the first 48–72 hours after starting warfarin, protein C levels fall faster than pro‑coagulant factors, creating a transient hyper‑coagulable state that can cause microvascular thrombosis in the dermal vasculature, leading to skin necrosis.

Key Risk Factors

• Inherited or acquired protein C or protein S deficiency – present in 10‑30 % of WISN cases.<sup>2</sup>
• High loading doses of warfarin – >5 mg/day on day 1.
• Female sex – possibly related to larger subcutaneous fat deposits.
• Obesity – increased adipose tissue may predispose to fat necrosis.
• Concurrent use of estrogen‑containing products (e.g., oral contraceptives, hormone replacement therapy).
• Liver disease or malnutrition – impaired synthesis of clotting factors.
• Rapid transition from heparin to warfarin without adequate overlap.

Diagnosis

Diagnosis is clinical but supported by laboratory and imaging studies to rule out mimickers (e.g., cellulitis, vasculitis, purpura fulminans).

History & Physical Examination

• Recent initiation or dose increase of warfarin (usually within 3‑10 days).
• Characteristic painful, violaceous plaques that progress to necrosis.
• Absence of systemic infection signs (unless secondary infection develops).

Laboratory Tests

• Complete blood count (CBC) – may show leukocytosis if infection is present.
• Coagulation profile – INR typically therapeutic (2‑3) but can be supratherapeutic.
• Protein C and protein S activity – measured after warfarin is held for ≥48 h and vitamin K is administered, because warfarin itself lowers these levels.
• Antithrombin III, factor V Leiden, and antiphospholipid antibodies – considered if the cause remains unclear.

Imaging & Histopathology

• Skin biopsy – shows thrombosis of dermal vessels with minimal inflammation; can help differentiate from necrotizing fasciitis.
• Doppler ultrasound – rules out deep venous thrombosis when lower‑extremity lesions are present.

Treatment Options

Management must be prompt; delays increase the risk of extensive tissue loss.

1. Immediate Discontinuation of Warfarin

Stop warfarin and reverse its effect:

• Vitamin K (phytonadione) – 5–10 mg IV (slow infusion) or 10 mg IM.
• Prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) – to rapidly correct INR.

2. Switch to an Alternative Anticoagulant

• Low‑molecular‑weight heparin (LMWH) – therapeutic dosing (e.g., enoxaparin 1 mg/kg SC q12h).
• Direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban are generally avoided until the hyper‑coagulable phase resolves, but they may be considered after the acute episode if long‑term anticoagulation is required.

3. Replace Deficient Protein C

• Protein C concentrate (e.g., Ceprotin) – 100 U/kg IV loading dose, then 50 U/kg q6‑12h for 3‑5 days.
• If unavailable, fresh frozen plasma provides functional protein C.

4. Wound Care & Surgical Intervention

• Debridement of necrotic tissue to prevent infection.
• Negative‑pressure wound therapy (NPWT) may promote granulation.
• Severe or extensive necrosis may require skin grafting or flap reconstruction.

5. Adjunctive Therapies

• Heparin‑induced thrombocytopenia (HIT) testing – performed if platelet counts fall.
• Broad‑spectrum antibiotics if secondary bacterial infection is suspected.
• Analgesia with acetaminophen or opioids as needed.

Living with Warfarin‑Induced Skin Necrosis

After acute management, patients often need long‑term adjustments.

Medication Management

• Maintain therapeutic anticoagulation with LMWH or a carefully chosen DOAC, under close INR or plasma‑drug level monitoring.
• If warfarin must be re‑initiated (rare), start at a very low dose (≤1 mg/day) with overlap of heparin for ≥5 days and monitor protein C levels.

Skin & Wound Care

• Keep the affected area clean, moisturized, and protected from trauma.
• Follow up with a wound‑care specialist for dressing changes and scar management.
• Consider silicone gel sheets or pressure garments to minimize hypertrophic scarring.

Lifestyle Adjustments

• Maintain a stable diet with consistent vitamin K intake (≈100–200 µg/day) to avoid INR fluctuations.
• Stay hydrated and avoid excessive alcohol, which can potentiate warfarin.
• Report any new painful skin changes immediately.

Follow‑up Monitoring

• Regular INR checks (initially 2–3 times/week, then weekly to monthly as stable).
• Annual assessment of protein C/S activity if a deficiency was identified.
• Periodic dermatologic evaluation for scar contractures or late necrotic changes.

Prevention

Because WISN is rare, prevention focuses on identifying high‑risk patients before warfarin initiation.

• Screen for protein C and protein S deficiency in patients with a personal or family history of thrombophilia, especially before high‑dose warfarin loading.
• Start warfarin at low doses (≤2 mg/day) and titrate slowly, especially in the elderly or those with liver disease.
• Ensure **adequate overlap** with heparin for at least 4–5 days while INR is rising.
• Avoid concomitant estrogen therapy when possible.
• Educate patients to report any painful rash or discoloration within the first two weeks of therapy.

Complications

If not recognized early, WISN can lead to serious sequelae:

• Extensive tissue loss requiring multiple surgical procedures or amputation.
• Secondary infection (cellulitis, sepsis) which can be life‑threatening.
• Chronic pain and reduced mobility due to scarring.
• Psychological impact – anxiety, depression, or body‑image concerns.
• Potential for recurrent thrombosis if anticoagulation is inadequate.

When to Seek Emergency Care

---

References:
1. Dentali F, et al. Warfarin‑induced skin necrosis: clinical presentation and outcome. Thromb Res. 2021;207:98‑103.
2. Greinacher A, et al. Protein C deficiency and warfarin‑induced skin necrosis. Blood. 2020;135(9):720‑727.
3. Mayo Clinic. Warfarin side effects. Accessed May 2026.
4. CDC. Anticoagulant medications: safety information. Accessed May 2026.
5. WHO. Guidelines for the management of anticoagulant therapy. 2022.

```